Evidence map›Paper›PMID 31480057›Full record

GuidelinePsychotherapy and psychosomatics2019

International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.

Ta-Wei Guu, David Mischoulon, Jerome Sarris, Joseph Hibbeln, Robert K McNamara, Kei Hamazaki, Marlene P Freeman, Michael Maes, Yutaka J Matsuoka, R H Belmaker and 5 more

Open access · bronzeAbstract readPractice GuidelineSystematic Review
PubMed Publisher
In one paragraph

Guideline in Psychotherapy and psychosomatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 7 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 7 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Transdiagnostic prevention in youth mental health, Part II: interventions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 7 countries.

Ta-Wei GuuDepartments of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.
David MischoulonDepression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jerome SarrisNICM, Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.
Joseph HibbelnSection on Nutritional Neuroscience, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.
Robert K McNamaraDepartment of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Kei HamazakiDepartment of Public Health, Faculty of Medicine, University of Toyama, Toyama, Japan.
Marlene P FreemanClinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael MaesDepartment of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Yutaka J MatsuokaDivision of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan.
R H BelmakerBen Gurion University of the Negev, Beersheba, Israel.
Felice JackaIMPACT SRC, Food and Mood Centre, School of Medicine, Faculty of Health, Deakin University, Sydney, New South Wales, Australia.
Carmine ParianteStress, Psychiatry and Immunology Laboratory, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Michael BerkDepartment of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia.
Wolfgang MarxIMPACT SRC, Food and Mood Centre, School of Medicine, Faculty of Health, Deakin University, Sydney, New South Wales, Australia.
Kuan-Pin SuDepartments of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan, cobolsu@gmail.com.
China Medical University · TWDeakin University · AUThe University of Melbourne · AUBen-Gurion University of the Negev · ILChulalongkorn University · THHarvard University · USKing's College London · GBMassachusetts General Hospital · USNational Center for Global Health and Medicine · JPNational Institute on Alcohol Abuse and Alcoholism · USUniversity of Cincinnati Medical Center · USUniversity of Toyama · JP

Funding

Nutritional Effects On Essential Fatty Acid CompositionZIAAA000235 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HIBBELN, JOSEPH · 2009 to 2020
$8.2M
Essential Fatty Acids In Psychiatric DisordersZIAAA000115 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HIBBELN, JOSEPH · 2009 to 2020
$7.8M
6 · The paper itself

Abstract

Major depressive disorder (MDD) is a complex mental illness with unmet therapeutic needs. The antidepressant effects of ω-3 polyunsaturated fatty acids (n-3 PUFAs) have been widely reported. The subcommittee of the International Society for Nutritional Psychiatry Research organized an expert panel and conducted a literature review and a Delphi process to develop a consensus-based practice guideline for clinical use of n-3 PUFAs in MDD. The guideline focuses on 5 thematic areas: general concepts, acute treatment strategy, depression recurrence monitoring and prevention, use in special populations, and potential safety issues. The key practice guidelines contend that: (1) clinicians and other practitioners are advised to conduct a clinical interview to validate clinical diagnoses, physical conditions, and measurement-based psychopathological assessments in the therapeutic settings when recommending n-3 PUFAs in depression treatment; (2) with respect to formulation and dosage, both pure eicosapentaenoic acid (EPA) or an EPA/docosahexaenoic acid (DHA) combination of a ratio higher than 2 (EPA/DHA >2) are considered effective, and the recommended dosages should be 1-2 g of net EPA daily, from either pure EPA or an EPA/DHA (>2:1) formula; (3) the quality of n-3 PUFAs may affect therapeutic activity; and (4) potential adverse effects, such as gastrointestinal and dermatological conditions, should be monitored, as well as obtaining comprehensive metabolic panels. The expert consensus panel has agreed on using n-3 PUFAs in MDD treatment for pregnant women, children, and the elderly, and prevention in high-risk populations. Personalizing the clinical application of n-3 PUFAs in subgroups of MDD with a low Omega-3 Index or high levels of inflammatory markers might be regarded as areas that deserve future research.

Indexed as

AgedAntidepressive AgentsBiomarkersChildDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3FemaleHumansMajor Depressive DisorderPregnancySocieties, MedicalAntidepressive AgentsBiomarkersDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3Docosahexaenoic acidEicosapentaenoic acidGuidelineMajor depressive disorderOmega-3 polyunsaturated fatty acids

Identifiers

PMID31480057
OpenAlexW2971713066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.